Scholar Rock resubmits apitegromab MAA to EMA for SMA

Scholar Rock (SRRK) said it has resubmitted its marketing authorisation application for apitegromab to the European Medicines Agency (EMA) for treatment of children and adults with spinal muscular atrophy (SMA).